Loading clinical trials...
Loading clinical trials...
An Open-label Dosimetry, Biodistribution, Tolerability and Safety Study of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Moderately and Severely Impaired and With Normal Renal Function.
Conditions
Interventions
AAA617
68Ga-PSMA-11
Locations
9
United States
Mount Sinai Hosp Med School
New York, New York, United States
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Vandœuvre-lès-Nancy, France
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Milan, Italy
Start Date
April 4, 2024
Primary Completion Date
June 17, 2026
Completion Date
June 17, 2026
Last Updated
March 6, 2026
NCT06615752
NCT03972657
NCT06134232
NCT06241846
NCT06344715
NCT04015622
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions